Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 02, 2022

SELL
$8.51 - $13.6 $1.44 Million - $2.31 Million
-169,665 Reduced 87.48%
24,284 $254,000
Q2 2022

Aug 01, 2022

BUY
$7.31 - $11.85 $533,476 - $864,801
72,979 Added 60.33%
193,949 $1.88 Million
Q1 2022

May 04, 2022

BUY
$7.35 - $10.63 $889,129 - $1.29 Million
120,970 New
120,970 $994,000
Q2 2020

Aug 07, 2020

SELL
$21.21 - $31.55 $131,883 - $196,177
-6,218 Closed
0 $0
Q1 2020

May 04, 2020

SELL
$18.43 - $38.04 $24,235 - $50,022
-1,315 Reduced 17.46%
6,218 $137,000
Q4 2019

Feb 06, 2020

BUY
$29.6 - $43.71 $33,033 - $48,780
1,116 Added 17.39%
7,533 $284,000
Q4 2019

Feb 04, 2020

SELL
$29.6 - $43.71 $19,595 - $28,936
-662 Reduced 9.35%
6,417 $226,000
Q3 2019

Nov 12, 2019

BUY
$29.87 - $42.22 $211,449 - $298,875
7,079 New
7,079 $219,000

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.